変異KRASの活性状態をターゲットにするための細胞チャペロンの化学改造
Christopher J Schulze1, Kyle J Seamon1, Yulei Zhao2
1Department of Biology, Revolution Medicines, Inc., Redwood City, CA 94063, USA.
まとめ
研究者はKRAS G12Cという がんを誘発する共通変異を標的とした 新しい小分子を開発しました この薬はサイクロフィリンAに新しい結合部位を作り,がんの成長を効果的に阻害し,モデルでは腫瘍の逆行を引き起こします.
科学分野:
- 腫瘍学
- 分子生物学
- 薬物の発見
背景:
- KRASを含む多くのタンパク質には,小分子阻害剤に適した結合ポケットがなく,それらを"薬剤耐性"と分類する.
- ミュータントKRASは多くの癌の主要な原動力ですが,その活性状態は治療目標として困難です.
- 難易度の高い結合部位を持つタンパク質を標的とする革新的な戦略が必要である.
研究 の 目的:
- KRAS G12Cの活性状態を標的にする薬剤付きインターフェースを作成できる新しい小分子を設計する.
- 臨床前がんモデルにおけるこの新しい治療戦略の有効性を評価する.
主な方法:
- サイクロフィリンA (CYPA) を再構成する天然製品にインスパイアされた小分子を設計しました.
- CYPA:ドラッグ:KRAS G12Cの 選択性三複合体を作りました
- 人間のがんモデルにおける腫瘍信号の抑制と腫瘍の回帰を評価した.
主要な成果:
- 設計された小さな分子は,KRAS G12Cのネオモルフなインターフェースを形成し,CYPAを成功裏に改造しました.
- CYPA:drug:KRAS G12Cトリコンプレックスは,腫瘍性シグナル伝達経路を効果的に無効化しました.
- KRAS G12C変異を有する複数のヒトがんモデルにおいて,有意な腫瘍回帰が観察されました.
結論:
- この新しいトリコンプレックス阻害戦略は,これまで薬剤で治療できなかったKRAS変異体を標的とする有効なアプローチを提供します.
- このアプローチは他の薬効性のない癌の誘発因子に対する 治療薬の開発の可能性を秘めています
- この戦略に基づくKRAS G12CおよびマルチRAS変異性阻害剤は,現在臨床試験中です.
関連する概念動画
Export of Misfolded Proteins out of the ER
3.7K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
3.7K
The Ras Gene
6.3K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.3K
Small GTPases - Ras and Rho
4.0K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
4.0K
Molecular Chaperones and Protein Folding
18.0K
The native conformation of a protein is formed by interactions between the side chains of its constituent amino acids. When the amino acids cannot form these interactions, the protein cannot fold by itself and needs chaperones. Notably, chaperones do not relay any additional information required for the folding of polypeptides; the native conformation of a protein is determined solely by its amino acid sequence. Chaperones catalyze protein folding without being a part of the folded protein.
The...
The...
18.0K
Bacterial Protein Maturation
36
Bacterial protein maturation is a tightly regulated process that ensures newly synthesized polypeptides achieve correct functional conformations. This maturation involves a series of modifications, folding events, and quality control steps, often assisted by specialized chaperone proteins.N-Terminal ModificationsThe maturation of bacterial polypeptides begins cotranslationally as the polypeptide exits the ribosome. The first amino acid, N-formylmethionine (fMet), is typically modified at the...
36
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K


